STOCK TITAN

Therma Bright Proposes to Amend Certain Warrants and Negotiates Debt Settlements

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Therma Bright (TBRIF) announced plans to amend the exercise price of 42,725,000 outstanding warrants from its June 2024 private placement, subject to TSXV approval. The warrants' exercise price will be modified to $0.05 per share until December 31, 2025, and $0.10 thereafter, with expiration remaining June 10, 2027. Of the total warrants, 8,750,000 are held by insiders, but due to TSXV policies, only 4,272,500 insider-held warrants can be repriced. Additionally, the company plans to settle $124,000 in debt through the issuance of 6,200,000 common shares at $0.02 per share, pending TSXV approval.
Therma Bright (TBRIF) ha annunciato l'intenzione di modificare il prezzo di esercizio di 42.725.000 warrant in circolazione, emessi nell'ambito di un collocamento privato di giugno 2024, soggetto all'approvazione della TSXV. Il prezzo di esercizio dei warrant sarà adeguato a 0,05$ per azione fino al 31 dicembre 2025, e successivamente a 0,10$, mantenendo la scadenza al 10 giugno 2027. Dei warrant totali, 8.750.000 sono detenuti da insider, ma in conformità alle politiche della TSXV, solo 4.272.500 warrant detenuti da insider possono essere modificati nel prezzo. Inoltre, la società prevede di estinguere un debito di 124.000$ tramite l'emissione di 6.200.000 azioni ordinarie al prezzo di 0,02$ per azione, sempre soggetto all'approvazione della TSXV.
Therma Bright (TBRIF) anunció planes para modificar el precio de ejercicio de 42.725.000 warrants pendientes, emitidos en una colocación privada de junio de 2024, sujeto a la aprobación de la TSXV. El precio de ejercicio de los warrants se ajustará a $0,05 por acción hasta el 31 de diciembre de 2025, y a $0,10 posteriormente, manteniendo la fecha de vencimiento el 10 de junio de 2027. De los warrants totales, 8.750.000 están en manos de insiders, pero debido a las políticas de la TSXV, solo 4.272.500 warrants de insiders pueden ser reajustados. Además, la compañía planea liquidar una deuda de $124.000 mediante la emisión de 6.200.000 acciones comunes a $0,02 por acción, pendiente de la aprobación de la TSXV.
Therma Bright(TBRIF)는 2024년 6월 사모 발행과 관련된 42,725,000개의 미행사 워런트의 행사 가격을 TSXV 승인 조건으로 수정할 계획을 발표했습니다. 워런트의 행사 가격은 2025년 12월 31일까지 주당 0.05달러로 조정되며, 이후에는 0.10달러로 변경되며 만기일은 2027년 6월 10일로 유지됩니다. 전체 워런트 중 8,750,000개는 내부자 보유분이나 TSXV 정책에 따라 내부자가 보유한 워런트 중 4,272,500개만 가격 조정이 가능합니다. 또한 회사는 TSXV 승인을 조건으로 0.02달러에 6,200,000주 보통주를 발행하여 124,000달러의 부채를 상환할 계획입니다.
Therma Bright (TBRIF) a annoncé son intention de modifier le prix d'exercice de 42 725 000 bons de souscription en circulation issus d'un placement privé de juin 2024, sous réserve de l'approbation de la TSXV. Le prix d'exercice des bons sera ajusté à 0,05 $ par action jusqu'au 31 décembre 2025, puis à 0,10 $ par action, la date d'expiration restant fixée au 10 juin 2027. Sur le total des bons, 8 750 000 sont détenus par des initiés, mais en raison des politiques de la TSXV, seuls 4 272 500 bons détenus par des initiés peuvent être revalorisés. De plus, la société prévoit de régler une dette de 124 000 $ par l'émission de 6 200 000 actions ordinaires à 0,02 $ chacune, sous réserve de l'approbation de la TSXV.
Therma Bright (TBRIF) kündigte Pläne an, den Ausübungspreis von 42.725.000 ausstehenden Warrants aus einer Privatplatzierung im Juni 2024, vorbehaltlich der Genehmigung durch die TSXV, zu ändern. Der Ausübungspreis der Warrants wird bis zum 31. Dezember 2025 auf 0,05 $ pro Aktie angepasst und danach auf 0,10 $, wobei das Ablaufdatum der 10. Juni 2027 bleibt. Von den insgesamt ausstehenden Warrants werden 8.750.000 von Insidern gehalten, aber aufgrund der TSXV-Richtlinien können nur 4.272.500 insidergehaltene Warrants neu bepreist werden. Zusätzlich plant das Unternehmen, eine Schuld in Höhe von 124.000 $ durch die Ausgabe von 6.200.000 Stammaktien zu je 0,02 $ zu begleichen, vorbehaltlich der Genehmigung durch die TSXV.
Positive
  • Debt settlement of $124,000 through share issuance helps preserve cash
  • Extended period for lower warrant exercise price could encourage warrant conversion and bring in capital
Negative
  • Significant warrant repricing from original terms indicates potential difficulties in raising capital
  • Share dilution through debt settlement at a low price of $0.02 per share
  • Large number of warrants (42.7M) could lead to substantial dilution if exercised

Toronto, Ontario--(Newsfile Corp. - June 5, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma Bright" or the "Company") a developer and investment partner specializing in advanced diagnostic and medical device technologies, announces that subject to the approval of the TSX Venture Exchange (the "TSXV"), the Company intends to amend the exercise price of an aggregate of 42,725,000 outstanding common share purchase warrants of the Company (the "Warrants") that were issued as part of the Company's private placement ("Private Placement") that closed on June 10, 2024. The Warrants had an original exercise price of $0.05 per share until June 10, 2025, and $0.10 per share thereafter until they expire on June 10, 2027. Following receipt of TSXV acceptance, the Company intends to amend the exercise price to $0.05 per share until December 31, 2025, and $0.10 per share thereafter. All other terms of the Warrants remain the same, including the expiry date of June 10, 2027.

8,750,000 Warrants are held by insiders of the Company. Pursuant to TSXV policies, no more than 10% of the total number of Warrants to be re-priced may be held by insiders. Accordingly, only 4,272,500 Warrants held by insiders will be subject to the foregoing re-pricing amendment and the remainder will retain their original exercise price terms.

The application of the Warrant amendments to insiders constitutes a "related party transaction" within Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The company is exempt from the requirements to obtain a formal valuation and minority shareholder approval in connection with the insiders' Warrant amendment participation in reliance on sections 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involves the insiders, exceeds 25% of the Company's market capitalization (as determined under MI 61-101).

The Company intends to issue an updating news release upon receipt, if any, of Warrant amendment approval.

Therma Bright also announces that it has negotiated debt settlements with arm's length creditors pursuant to which it proposes to settle aggregate debt of $124,000 in consideration for which it will issue an aggregate of 6,200,000 common shares at a deemed price of $0.02 per share, subject to acceptance by the TSXV.

About Therma Bright Inc.

Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.

Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com

Follow us X

FORWARD-LOOKING STATEMENTS

Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as current and future development of Therma's products and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254584

FAQ

What changes is Therma Bright (TBRIF) making to its warrant terms?

Therma Bright is amending the exercise price of 42.7M warrants to $0.05 per share until December 31, 2025, and $0.10 thereafter, with expiration on June 10, 2027.

How much debt is Therma Bright (TBRIF) settling through share issuance?

Therma Bright is settling $124,000 in debt by issuing 6.2M common shares at $0.02 per share, subject to TSXV approval.

How many insider-held warrants of Therma Bright (TBRIF) are eligible for repricing?

Only 4,272,500 insider-held warrants can be repriced due to TSXV policies limiting insider repricing to 10% of total warrants.

What is the expiration date for Therma Bright's (TBRIF) amended warrants?

The warrants will expire on June 10, 2027, which remains unchanged from the original terms.

What is the price per share for Therma Bright's (TBRIF) debt settlement?

The debt settlement shares are being issued at a deemed price of $0.02 per share.
Therma Bright Inc

OTC:TBRIF

TBRIF Rankings

TBRIF Latest News

TBRIF Stock Data

9.70M
422.57M
7.02%
Medical Devices
Healthcare
Link
Canada
Toronto